Charles River plays an integral role in the preclinical discovery and development of new therapies and treatments in the field of oncology by providing non-GLP in vivo and in vitro studies for compound screening and efficacy, as well as a broad range of models and support services.

Focusing on oncology, our North Carolina site’s drug discovery capabilities include:

  • In vitro assay services
  • Patient-derived human tumor grafts and conventional human xenograft models in mice and rats
  • Humanized, syngeneic and orthotopic models
  • Combination chemotherapy and radiotherapy
  • Tissue biomarker analysis and plasma biomarker testing

Download our Morrisville At-a-Glance sheet for more information on the facility and capabilities.